Summary: In a manufacturer-sponsored post hoc analysis of 3,792 SURPASS participants, tirzepatide lowered HbA1c (-2.6% vs -2.4%) and body weight (-14 vs -13 kg) to a similar degree in adults with early-onset (diagnosed before age 40) versus later-onset type 2 diabetes at week 40. Early-onset participants started with worse glycaemia and metabolic health but responded comparably.
PICO Summary
| Element | Detail |
|---|---|
| Population | 3,792 adults with type 2 diabetes pooled from the SURPASS-1, SURPASS-2 and SURPASS-3 randomised trials; stratified into early-onset (diagnosed before age 40) versus later-onset subgroups. Post hoc, subgroup analysis of an international trial programme. |
| Intervention | Once-weekly subcutaneous tirzepatide (dual GIP/GLP-1 receptor agonist) at the doses studied within each parent trial; the early-onset subgroup. Outcomes assessed on assigned treatment without rescue medication. |
| Comparison | The later-onset (diagnosed at or after age 40) subgroup, also treated with tirzepatide. This analysis compared age-at-diagnosis subgroups, not tirzepatide against another drug or standard care. |
| Outcome | At week 40 (SURPASS-1 and -2), changes were similar in early-onset versus later-onset subgroups: HbA1c -2.6% vs -2.4%; body weight -14 vs -13 kg; waist circumference -10 vs -10 cm; triglycerides -26% vs -24%; HDL +7% vs +7%; systolic blood pressure -6 vs -7 mmHg. At baseline, early-onset participants had longer diabetes duration (9 vs 7 years, P<0.001), higher HbA1c (8.5% vs 8.2%, P<0.001), higher weight (97 vs 93 kg, P<0.001) and higher BMI (35 vs 34 kg/m2, P<0.001). No between-subgroup confidence intervals, p values, ARR or NNT were reported for the week-40 treatment-effect differences; these are descriptive. |
Expert Commentary
The verdict is reassuring but modest in what it actually establishes. This is a post hoc, descriptive subgroup analysis, so it generates a hypothesis rather than proving one: tirzepatide appears to deliver comparable HbA1c, weight and cardiometabolic improvements whether type 2 diabetes was diagnosed before or after age 40, despite early-onset patients presenting with longer duration, higher HbA1c and greater adiposity. Several cautions are warranted. The study was sponsored by the manufacturer and several authors are company employees, which is disclosed but relevant. The parent SURPASS trials were open-label for the comparator arms, and this analysis pooled across trials with differing comparators and follow-up windows. Most importantly, the headline early-onset versus later-onset contrasts are reported as raw differences without confidence intervals or significance testing, so apparent similarity should not be read as a formal demonstration of non-difference. The single most weighing limitation is that subgroups were defined after randomisation and were not powered to detect interaction by age at diagnosis. Can I use this with my patients? Cautiously yes, for a younger adult with early-onset type 2 diabetes who is already a tirzepatide candidate, this supports expecting a response broadly similar to older patients rather than a blunted one. I would still want dedicated prospective and longer-term outcome data, particularly on durability and complications, before treating age at onset as a settled non-modifier of benefit.
References
Zeitler P, Galindo RJ, Davies MJ, et al. Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Diabetes Care. 2024;47(6):1056-1064. doi:10.2337/dc23-2356
